Posted by Michael Wonder on 27 Feb 2019
Celgene Corporation announces key regulatory update for Revlimid in lymphoma
26 February 2019 - U.S. FDA grants priority review for Revlimid (lenalidomide) in combination with rituximab for previously treated follicular and marginal zone lymphoma.
Celgene Corporation today announced that the U.S. FDA has granted priority review designation for the company’s supplemental new drug application for Revlimid (lenalidomide) in combination with rituximab for the treatment of patients with previously treated follicular and marginal zone lymphoma.
Under the Prescription Drug User Fee Act, the FDA has set its action date as 27 June 2019.
